+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Chronic Myelogenous Leukemia Therapeutics Market - Global Forecast 2025-2030- Product Image
Chronic Myelogenous Leukemia Therapeutics Market - Global Forecast 2025-2030- Product Image
Sale

Chronic Myelogenous Leukemia Therapeutics Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 180 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010863
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Chronic Myelogenous Leukemia Therapeutics Market is witnessing transformative advances as evolving therapies, innovative monitoring strategies, and shifting policy dynamics converge to shape clinical decision-making and commercial opportunities.

Market Snapshot: Chronic Myelogenous Leukemia Therapeutics Market Overview

The Chronic Myelogenous Leukemia Therapeutics Market grew from USD 8.27 billion in 2024 to USD 8.94 billion in 2025. It is expected to continue expanding at a CAGR of 7.78%, reaching USD 12.97 billion by 2030. Growth is attributed to significant advances in targeted therapies, the broader adoption of digital monitoring tools, and adaptive treatment models tailored for diverse patient populations.

Scope & Segmentation

  • Therapy Type: Chemotherapy agents, combination regimens, and tyrosine kinase inhibitors spanning first, second, and third generation compounds refine the treatment arsenal.
  • Treatment Line: Includes first, second, and subsequent lines of therapy, with adaptation based on tolerance and resistance.
  • Mechanism of Action: Covers cytotoxic chemotherapy, combination agent modalities, and precision tyrosine kinase inhibition approaches.
  • Route of Administration: Options include oral formulations and parenteral delivery via intravenous or subcutaneous injection.
  • End User: Hospitals, specialty centers, clinics, and home care settings are critical access points for therapy and monitoring.
  • Distribution Channel: Spans hospital pharmacies, online pharmacies, and retail outlets, supporting access across geographies.
  • Dosage Form: Capsules, tablets, injectables, and powder for injection support clinical choice and patient needs.
  • Patient Age Group: Adult, geriatric, and pediatric populations require tailored therapeutic strategies and adherence support.
  • Regions Covered: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, UAE, Saudi Arabia, South Africa, and more), and Asia-Pacific (including China, India, Japan, Australia, South Korea, and others).
  • Key Companies: Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Viatris Inc., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited.

Key Takeaways

  • Targeted therapies continue to transform patient management, with next-generation agents addressing resistance and intolerance to first-generation treatments.
  • Combination regimens leveraging tyrosine kinase inhibitors with chemotherapy or immunologic agents are advancing response durability and may enable treatment-free remission in some settings.
  • Digital health integration, including remote molecular monitoring and telemedicine, enhances patient adherence and enables personalized adjustment of therapy and follow-up schedules.
  • Regional market dynamics, such as established reimbursement frameworks in the Americas and cost-sensitivity in Asia-Pacific, require adaptable access and pricing strategies informed by real-world evidence and local clinical needs.
  • Pipeline innovation emphasizes late-stage studies on treatment-free endpoints and mechanism-based therapies, positioning organizations to address unmet needs and heighten differentiation.

Tariff Impact

  • New tariff regulations implemented in 2025 have influenced global supply chains for active pharmaceutical ingredients, prompting manufacturers to diversify sourcing and explore cost-effective production routes.
  • These changes have downstream effects on acquisition costs, requiring hospitals and payers to adapt procurement practices and negotiation strategies to preserve therapy access.
  • Collaborative purchasing alliances and robust inventory strategies are increasingly critical to mitigating supply volatility.

Methodology & Data Sources

This market analysis leverages a blend of primary interviews with clinical stakeholders and industry experts, as well as secondary research from peer-reviewed publications, clinical trial registries, and trade sources. Rigorous data triangulation and scenario modeling help ensure the reliability and relevance of all insights presented.

Why This Report Matters

  • Guides strategic planning by clarifying therapeutic innovations, market access levers, and emerging risk factors in the CML therapeutics space.
  • Enables stakeholders to benchmark competitive positioning and identify regional partnership opportunities for growth and resilience.
  • Supports resource allocation and investment decisions informed by comprehensive segmentation intelligence and evidence-based projections.

Conclusion

The Chronic Myelogenous Leukemia Therapeutics Market offers a dynamic environment shaped by scientific innovation, adaptive supply strategies, and evolving access models. Senior leaders can use these insights to align priorities, strengthen resilience, and pursue new opportunities in this evolving sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging efficacy and safety profiles of third-generation tyrosine kinase inhibitors in refractory CML patients
5.2. Market penetration and pricing dynamics of generic imatinib following patent expiry in key global markets
5.3. Development and regulatory progress of allosteric BCR-ABL inhibitors targeting resistant CML clones
5.4. Utilization of minimal residual disease monitoring via digital PCR to personalize CML treatment regimens
5.5. Advancements in combination therapy approaches integrating immunomodulators with TKIs for CML management
5.6. Impact of new oral formulation adherence support programs on long-term outcomes in CML patients
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Chronic Myelogenous Leukemia Therapeutics Market, by Therapy Type
8.1. Introduction
8.2. Chemotherapy
8.2.1. Busulfan
8.2.2. Hydroxyurea
8.2.3. Interferon Alfa
8.3. Combination Agents
8.3.1. Tyrosine Kinase Inhibitor With Chemotherapy
8.3.2. Tyrosine Kinase Inhibitor With Monoclonal Antibody
8.4. Tyrosine Kinase Inhibitors
8.4.1. First Generation
8.4.1.1. Imatinib
8.4.2. Second Generation
8.4.2.1. Bosutinib
8.4.2.2. Dasatinib
8.4.2.3. Nilotinib
8.4.3. Third Generation
8.4.3.1. Ponatinib
9. Chronic Myelogenous Leukemia Therapeutics Market, by Treatment Line
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line And Beyond
10. Chronic Myelogenous Leukemia Therapeutics Market, by Mechanism Of Action
10.1. Introduction
10.2. Chemotherapy
10.3. Combination Agents
10.4. Tyrosine Kinase Inhibition
11. Chronic Myelogenous Leukemia Therapeutics Market, by Route Of Administration
11.1. Introduction
11.2. Oral
11.3. Parenteral
11.3.1. Intravenous
11.3.2. Subcutaneous
12. Chronic Myelogenous Leukemia Therapeutics Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care Settings
12.4. Hospitals
12.5. Specialty Centers
13. Chronic Myelogenous Leukemia Therapeutics Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Chronic Myelogenous Leukemia Therapeutics Market, by Dosage Form
14.1. Introduction
14.2. Capsule
14.3. Injection
14.4. Powder For Injection
14.5. Tablet
15. Chronic Myelogenous Leukemia Therapeutics Market, by Patient Age Group
15.1. Introduction
15.2. Adult Patients
15.3. Geriatric Patients
15.4. Pediatric Patients
16. Americas Chronic Myelogenous Leukemia Therapeutics Market
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. Argentina
17. Europe, Middle East & Africa Chronic Myelogenous Leukemia Therapeutics Market
17.1. Introduction
17.2. United Kingdom
17.3. Germany
17.4. France
17.5. Russia
17.6. Italy
17.7. Spain
17.8. United Arab Emirates
17.9. Saudi Arabia
17.10. South Africa
17.11. Denmark
17.12. Netherlands
17.13. Qatar
17.14. Finland
17.15. Sweden
17.16. Nigeria
17.17. Egypt
17.18. Turkey
17.19. Israel
17.20. Norway
17.21. Poland
17.22. Switzerland
18. Asia-Pacific Chronic Myelogenous Leukemia Therapeutics Market
18.1. Introduction
18.2. China
18.3. India
18.4. Japan
18.5. Australia
18.6. South Korea
18.7. Indonesia
18.8. Thailand
18.9. Philippines
18.10. Malaysia
18.11. Singapore
18.12. Vietnam
18.13. Taiwan
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Novartis AG
19.3.2. Bristol-Myers Squibb Company
19.3.3. Pfizer Inc.
19.3.4. Takeda Pharmaceutical Company Limited
19.3.5. Sun Pharmaceutical Industries Limited
19.3.6. Teva Pharmaceutical Industries Ltd.
19.3.7. Viatris Inc.
19.3.8. Dr. Reddy’s Laboratories Ltd
19.3.9. Aurobindo Pharma Limited
19.3.10. Cipla Limited
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 18. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 20. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 31. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET: RESEARCHAI
FIGURE 32. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 33. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 34. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BUSULFAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BUSULFAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HYDROXYUREA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HYDROXYUREA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTERFERON ALFA, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTERFERON ALFA, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITOR WITH CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITOR WITH CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITOR WITH MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITOR WITH MONOCLONAL ANTIBODY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMATINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMATINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BOSUTINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BOSUTINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DASATINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DASATINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY NILOTINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY NILOTINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PONATINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PONATINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITION, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITION, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY POWDER FOR INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY POWDER FOR INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 183. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 184. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 185. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 186. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 187. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2024 (USD MILLION)
TABLE 188. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2025-2030 (USD MILLION)
TABLE 189. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 190. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 191. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2024 (USD MILLION)
TABLE 192. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2025-2030 (USD MILLION)
TABLE 193. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2024 (USD MILLION)
TABLE 194. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2025-2030 (USD MILLION)
TABLE 195. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 196. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 197. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 198. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 199. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 200. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 201. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 204. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 205. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 210. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 211. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 212. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 213. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 214. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 215. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 216. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 217. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2024 (USD MILLION)
TABLE 218. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2025-2030 (USD MILLION)
TABLE 219. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 220. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 221. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2024 (USD MILLION)
TABLE 222. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2025-2030 (USD MILLION)
TABLE 223. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2024 (USD MILLION)
TABLE 224. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2025-2030 (USD MILLION)
TABLE 225. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 226. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 227. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 228. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 229. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 230. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 231. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 234. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 235. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 240. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 241. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 242. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 243. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 244. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COMBINATION AGENTS, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2025-2030 (USD MILLION)
TABLE 255. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
TABLE 256. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2025-2030 (USD MILLION)
TABLE 257. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 258. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 261. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 262. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL CHR

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Chronic Myelogenous Leukemia Therapeutics market report include:
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Dr. Reddy’s Laboratories Ltd
  • Aurobindo Pharma Limited
  • Cipla Limited

Table Information

Report AttributeDetails
No. of Pages180
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 8.94 Billion
Forecasted Market Value ( USD ) by 2030 $ 12.97 Billion
Compound Annual Growth Rate7.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Chronic Myelogenous Leukemia Therapeutics Market 2024-2028 - Product Image

Chronic Myelogenous Leukemia Therapeutics Market 2024-2028

  • Report
  • 146 Pages
  • Global
From
Acute Myelogenous Leukemia (AML) - Pipeline Insight, 2025 - Product Image

Acute Myelogenous Leukemia (AML) - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Myeloproliferative Disorders Drugs Market Size, Share & Trends Analysis Report By Indication, By Treatment Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Myeloproliferative Disorders Drugs Market Size, Share & Trends Analysis Report By Indication, By Treatment Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Acute Myeloid Leukemia Market Report and Forecast 2025-2034 - Product Image

Acute Myeloid Leukemia Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Treating Chronic Myeloid Leukemia by Phase Market - Global Forecast 2025-2030 - Product Image

Treating Chronic Myeloid Leukemia by Phase Market - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.